Great Elm Group (GEG) Q3 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Adam Yates - Managing DirectorJason Reese - CEO & Executive ChairmanKeri Davis - CFO & Treasurer Operator Ladies and gentlemen, greetings, and welcome to the Great Elm Group Fiscal twenty twenty five Third Quarter Conference Call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference call is being recorded. It is ...

Financial Data and Key Metrics Changes - The company achieved record total net revenue of $52.6 million for the first quarter, with MACI revenue of $46.3 million, Epicel revenue of $5 million, and NexoBrid revenue of $1.3 million [13] - MACI revenue grew by 15% year-over-year, which adjusts to approximately 17% growth when accounting for one fewer selling day in the quarter [14] - NexoBrid revenue increased by 207% year-over-year and 31% sequentially [14] - The net loss for the quarter was $11.2 million, or $0.23 per share, with non-GAAP adjusted EBITDA of $3.2 million, representing 6% of net revenue [16] Business Line Data and Key Metrics Changes - MACI had a strong quarter with record revenue exceeding $46 million, driven by strong underlying fundamentals and a growing surgeon customer base [6][5] - NexoBrid's revenue growth was significant, with over 200% increase compared to the previous year, indicating strong market penetration [10] - Epicel revenue was lower than anticipated due to a high percentage of canceled cases, but there was a strong start to the second quarter with graft volumes exceeding the first quarter [11][12] Market Data and Key Metrics Changes - The company expects total revenue growth of 22% to 25% for the second quarter, with MACI revenue projected to be approximately $54 million [18] - The addressable market for MACI is estimated at 60,000 patients annually, with significant opportunities in femoral condyle and trochlear defects [26][20] Company Strategy and Development Direction - The company is advancing the MACI Ankle Development Program and plans to initiate a Phase III clinical study in the second half of the year, which represents a substantial long-term growth driver [20] - The company plans to expand its MACI sales force in the second half of the year to support growth driven by MACI Arthro [10][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about strong second quarter performance based on positive trends observed in the first quarter, reaffirming full-year revenue guidance of 20% to 23% growth [5][17] - The company anticipates minimal impact from tariffs due to its domestic manufacturing and significant safety stock of materials [17] Other Important Information - The company generated $6.6 million in operating cash flow and ended the quarter with approximately $162 million in cash and no debt [16] - Management raised profitability guidance for the year, expecting gross margins to reach 75% and adjusted EBITDA margins to reach 26% [18] Q&A Session Summary Question: Can you discuss the market opportunity for femoral condyle and trochlear specifically? - Management indicated that the MACI Arthro instruments are designed for femoral condyle defects, which represent a significant portion of the addressable market, and there is potential for treating trochlear defects as well [26][27] Question: How do you see seasonality and pacing for MACI in the second half of the year? - Management noted that while MACI typically follows a prescriptive pattern, strong leading indicators suggest potential for stronger growth in the second half of the year [32][33] Question: What is the contribution of MACI Arthro to first quarter numbers? - Management acknowledged that while there was some incremental impact from MACI Arthro, the full effect is expected to be seen in the second half of the year [38][40] Question: How have recent trade war headlines impacted international views on MACI? - Management stated that they are evaluating potential for MACI outside the U.S. but will consider tariffs and trade impacts before making decisions [92] Question: Can you provide insights on conversion rates for MACI Arthro procedures? - Management indicated that it is early to assess conversion rates, but they expect higher rates over time due to the less invasive nature of the procedure [57][66] Question: What are the dynamics of cross-selling opportunities between Epicel and NexoBrid? - Management confirmed that they are seeing biopsies from previously dormant accounts and expect this trend to continue as they cross-sell products [61] Question: Can you elaborate on the sales force expansion plans? - Management indicated that while the expansion is not full-scale this year, they are preparing to add resources to support expected growth [80][81]

Liberty Latin America Ltd (LILA) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Sean Fitzgerald - VP - TaxBalan Nair - President, Director & CEOChris Noyes - SVP & CFOVitor Tomita - VP - Equity ResearchJose Herrera - AVPLeonardo Curtidor - Equity Research Associate Conference Call Participants Chris Hoare - Lead AnalystMatthew Harrigan - Senior Analyst Operator Good morning, ladies and gentlemen, and thank you for standing by. Today's call is being recorded. I'll now turn call over to S ...

Gladstone Commercial (GOOD) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants David Gladstone - Founder, Chairman & CEOMichael Licalsi - General Counsel & SecretaryBuzz Cooper - PresidentGary Gerson - CFO & Assistant TreasurerGaurav Mehta - Managing DirectorCraig Kucera - MD - Equity ResearchDave Storms - Director of Equity Research Conference Call Participants John Massocca - Senior Research Analyst Operator As a reminder, this conference is being recorded. It is now my pleasure to introd ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $395 million, representing a 25% increase from Q1 2024, while adjusted EBITDA was $94 million, up 95% from the previous year [18][19] - The company ended the quarter with $230 million in cash and a net debt leverage ratio of 1.2x, below the target of 2x [19][20] Business Line Data and Key Metrics Changes - Payment Software segment revenue grew 42% year-over-year, with adjusted EBITDA more than doubling compared to Q1 2024 [10][18] - Biller segment revenue increased by 11%, with adjusted EBITDA rising by 1% from Q1 2024 [18][19] Market Data and Key Metrics Changes - The company reported strong cash flow growth with operating cash flow of $78 million for the quarter [19] - The company has not seen material impacts from geopolitical uncertainties, including trade discussions, and remains focused on broader strategies [16][20] Company Strategy and Development Direction - The company has combined its Bank and Merchant segments into a new business unit called Payments Software, which has generated new pipeline opportunities and improved operational efficiency [9][10] - The launch of the next-generation payments hub solution, named Kinetic, aims to expand the addressable market to include midsize banks and non-bank financial institutions [11][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving full-year targets, citing a strong start to the year and healthy customer demand despite macroeconomic uncertainties [16][17] - The company raised its full-year revenue guidance to a range of $1.69 billion to $1.72 billion, with adjusted EBITDA expected between $480 million and $495 million [22] Other Important Information - The company repurchased approximately 1 million shares year-to-date for $52 million, with $320 million remaining on its share repurchase authorization [19] - Scott Behrens, the CFO, announced plans for retirement, which will be managed through a succession plan [24][26] Q&A Session Summary Question: Current environment and customer behavior - Management noted no negative impacts from macroeconomic uncertainties, with customers showing a willingness to invest in modernization [31][35] Question: Exposure to stablecoins and cross-border payments - The company facilitates cross-border payments and is exploring stablecoin opportunities, although current volumes are small [39][42] Question: Payment Software segment growth expectations - Management expects continued growth in the Payment Software segment, with a focus on recurring revenue and license deals [50][55] Question: Partnership with Ingo Payments and Speedpay - The partnership aims to enhance digital disbursements, expanding the company's capabilities beyond bill payments [56][62] Question: Impact of recent mergers in the industry - Management expressed optimism about potential opportunities arising from the mergers of Global Payments and FIS, emphasizing strong existing relationships [64][65] Question: Revenue contribution from real-time payments - Real-time payments account for about 10% of overall business and are expected to grow at double digits, though with some quarter-to-quarter volatility [86][87] Question: Traction in different product areas - The company saw significant traction in issuing and acquiring solutions, particularly in the Asia Pacific region [92][95]

Catalyst Pharmaceuticals (CPRX) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Michael Kalb - Executive VP & CFORichard Daly - President & CEOJeff Del Carmen - Executive Vice President, Chief Commercial OfficerBenjamin Paluch - Equity Research Senior Associate - BiotechCharles Duncan - Managing DirectorRohan Mathur - Biopharma Equity Research AssociateGary Ingenito - Chief Medical & Regulatory OfficerFelix Ampomah - Senior Associate Conference Call Participants Asim Rana - Equity Analys ...

DENTSPLY SIRONA (XRAY) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Andrea Daley - Vice President, Investor RelationsSimon Campion - CEO, President & DirectorJonathan Block - Managing Director Conference Call Participants Elizabeth Anderson - Senior Managing Director & Research AnalystMichael Cherny - Senior Managing Director & Senior Research AnalystDylan Finley - Equity Research AnalystDavid Saxon - Senior AnalystSimran Kaur - Equity Research AnalystJeffrey Johnson - Managing Direct ...

N-Able (NABL) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Griffin Gyr - Investor Relations ManagerJohn Pagliuca - CEO, President & DirectorTim O’Brien - EVP & CFOBrian Essex - Executive DirectorJason Ader - Co-Group Head - Technology, Media & CommunicationsJoe Vandrick - Associate Director - Equity Research Conference Call Participants Mike Cikos - Senior AnalystMatt Hedberg - Managing Director & Software Research AnalystKeith Bachman - Senior Research Analyst Operator everyone. Than ...

Kyndryl (KD) Q4 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Lori Chaitman - Global Head, IRMartin Schroeter - Chairman & CEODavid Wyshner - CFOIan Zaffino - Managing DirectorDivya Goyal - Director - Equity Research - Technology, Software & ServicesTyler DuPont - Equity Research Associate Conference Call Participants Jamie Friedman - Senior FinTech and IT Services Research AnalystTien-tsin Huang - Senior Analyst Operator Good day, and thank you for standing by. Welcome to the Kindrel Fou ...

SharkNinja (SN) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants James Lamb - SVP - IR & TreasuryMark Barrocas - Director & CEOPatraic Reagan - Chief Financial OfficerRandal Konik - Managing DirectorSteven Forbes - Senior Managing Director Conference Call Participants Brooke Roach - AnalystRupesh Parikh - Senior Equity Research Analyst Operator Thank you. I would now like to pass the conference over to your host, James Lamb, Senior Vice President of Investor Relations and Treasury. Thank ...